Cargando…

P1562: CHARACTERIZING IRON OVERLOAD BY AGE IN PATIENTS DIAGNOSED WITH PYRUVATE KINASE DEFICIENCY – A DESCRIPTIVE ANALYSIS FROM THE PEAK REGISTRY

Detalles Bibliográficos
Autores principales:	Bianchi, P., Grace, R. F., Vives Corrons, J.-L., Glader, B., Glenthøj, A., Kanno, H., Kuo, K. H., Lander, C., Layton, D. M., Pospíŝilová, D., Viprakasit, V., Williams, J., Yan, Y., McGee, B., van Beers, E. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429064/ http://dx.doi.org/10.1097/01.HS9.0000849104.75259.69

Ejemplares similares

The Pyruvate Kinase Deficiency Global Longitudinal (Peak) Registry: rationale and study design
por: Grace, Rachael F, et al.
Publicado: (2023)

P1542: COMORBIDITIES AND COMPLICATIONS ACROSS GENOTYPES IN ADULT PATIENTS WITH PYRUVATE KINASE DEFICIENCY: ANALYSIS FROM THE PEAK REGISTRY
por: Glenthøj, A., et al.
Publicado: (2022)

P1479: COMORBIDITIES AND COMPLICATIONS IN ADULTS WITH PYRUVATE KINASE DEFICIENCY ACCORDING TO HEMOGLOBIN STRATA – A DESCRIPTIVE ANALYSIS FROM THE PEAK REGISTRY
por: Pospíŝilová, Dagmar, et al.
Publicado: (2023)

P1565: MITAPIVAT IMPROVES INEFFECTIVE ERYTHROPOIESIS AND REDUCES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY
por: van Beers, E. J., et al.
Publicado: (2022)

P1544: BONE MINERAL DENSITY REMAINS STABLE IN PYRUVATE KINASE DEFICIENCY PATIENTS RECEIVING LONG-TERM TREATMENT WITH MITAPIVAT
por: Al-Samkari, H., et al.
Publicado: (2022)

The variable manifestations of disease in pyruvate kinase deficiency and their management
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

P1545: DURABILITY OF HEMOGLOBIN RESPONSE AND REDUCTION IN TRANSFUSION BURDEN IS MAINTAINED OVER TIME IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT IN A LONG-TERM EXTENSION STUDY
por: Grace, R. F., et al.
Publicado: (2022)

P1497: MITAPIVAT IMPROVES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED
por: van Beers, Eduard, et al.
Publicado: (2023)

PB2248: CONCOMITANT HEREDITARY SPHEROCYTOSIS AND PYRUVATE KINASE DEFICIENCY IN A SPANISH FAMILY WITH CHRONIC HEMOLYTIC ANEMIA. CONTRIBUTION OF LASER EKTACYTOMETRY TO CLINICAL DIAGNOSIS
por: Vives Corrons, J.-L., et al.
Publicado: (2022)

P1548: LONG-TERM TREATMENT WITH ORAL MITAPIVAT IS ASSOCIATED WITH NORMALIZATION OF HEMOGLOBIN LEVELS IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY
por: Barcellini, W., et al.
Publicado: (2022)

P1473: CLINICALLY RELEVANT HEMOGLOBIN RESPONSE IN ADULTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT – A SUB-ANALYSIS OF THE ACTIVATE TRIAL
por: Al-Samkari, Hanny, et al.
Publicado: (2023)

Visceral Leishmaniasis during Italian Renaissance, 1522–1562
por: Nerlich, Andreas G., et al.
Publicado: (2012)

P1551: CONFORMATIONAL STUDY OF PYRUVATE KINASE DEFICIENT VARIANTS WITH HEMOLYTIC ANEMIA. THE RELATIONSHIPS BETWEEN THE LOSS OF ENZYME FUNCTION AND STRUCTURAL DISRUPTION
por: Jorda, L., et al.
Publicado: (2022)

Comorbidities and complications in adults with pyruvate kinase deficiency
por: Boscoe, Audra N., et al.
Publicado: (2021)

Concomitant Hereditary Spherocytosis and Pyruvate Kinase Deficiency in a Spanish Family with Chronic Hemolytic Anemia: Contribution of Laser Ektacytometry to Clinical Diagnosis
por: Vives Corrons, Joan-Lluis, et al.
Publicado: (2022)

Erythrocyte pyruvate kinase deficiency: 2015 status report
por: Grace, Rachael F., et al.
Publicado: (2015)

1562. Safety and Efficacy of High-Dose Cefazolin Therapy in Obesity
por: Simpson, Timothy, et al.
Publicado: (2019)

1562MO Effectiveness of COVID-19 vaccination in cancer patients: A nationwide Veterans Affairs study
por: Wu, J.T-Y., et al.
Publicado: (2021)

P1562: THE FIRST TWO YEARS OF THE EUROPEAN VACCELERATE VOLUNTEER REGISTRY
por: Salmanton-García, Jon, et al.
Publicado: (2023)

P1735: IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN MITAPIVAT-TREATED PATIENTS WITH PYRUVATE KINASE DEFICIENCY: A DESCRIPTIVE ANALYSIS FROM THE PHASE 3 ACTIVATE TRIAL
por: Kuo, K. H., et al.
Publicado: (2022)

Treating iron overload in patients with non-transfusion-dependent thalassemia
por: Taher, Ali T, et al.
Publicado: (2013)

Matrix Metalloproteinase-9 −1562C/T Gene Polymorphism Is Associated with Diabetic Nephropathy
por: Feng, Shufen, et al.
Publicado: (2016)

Prognostic Value of MMP-9 -1562 C/T Gene Polymorphism in Patients With Sepsis
por: Bermúdez-Mejía, César, et al.
Publicado: (2019)

1562. Impact of Skin Biopsy on Diagnosing Infections and Changing Treatment in Cancer Patients with New Skin Rash
por: Jakharia, Niyati, et al.
Publicado: (2018)

P1477: MITAPIVAT EFFICACY IN ADULTS WITH PYRUVATE KINASE DEFICIENCY AND BASELINE HEMOGLOBIN LEVELS >10 G/DL
por: Grace, Rachael F., et al.
Publicado: (2023)

Does the functional polymorphism-1562C/T of MMP-9 gene influence brain disorders?
por: Pabian-Jewuła, Sylwia, et al.
Publicado: (2023)

Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias
por: Al-Samkari, Hanny, et al.
Publicado: (2021)

A meta-analysis of MMP-9 promoter −1562 C/T polymorphism on susceptibility of chronic periodontitis
por: Ajmera, Deepal Haresh, et al.
Publicado: (2016)

Iron overload across the spectrum of non‐transfusion‐dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions
por: Porter, John B., et al.
Publicado: (2016)

Manual de técnicas de laboratorio en hematología
por: Vives Corrons, Joan Lluís
Publicado: (2006)

The MMP-9 -1562 C/T Polymorphism in the Presence of Metabolic Syndrome Increases the Risk of Clinical Events in Patients with Coronary Artery Disease
por: Opstad, Trine B., et al.
Publicado: (2014)

Matrix Metalloproteinase-9 -1562C/T Promoter Polymorphism Confers Risk for COPD: A Meta-Analysis
por: Chen, Lei, et al.
Publicado: (2013)

Correlation between the −1562C/T polymorphism in the matrix metalloproteinase-9 gene and hemorrhagic transformation of ischemic stroke
por: ZHANG, XIAOMAN, et al.
Publicado: (2015)

MMP-9-C1562T polymorphism and susceptibility to chronic obstructive pulmonary disease: A meta-analysis
por: Zhao, Rongrong, et al.
Publicado: (2020)

Who should be eligible for gene therapy clinical trials in red blood cell pyruvate kinase deficiency (PKD)?: Toward an expanded definition of severe PKD
por: Schwartz, Jonathan D., et al.
Publicado: (2022)

Manual de técnicas de laboratorio en hematología /
por: Vives i Corrons, Joan Lluís
Publicado: (1987)

Manual de técnicas de laboratorio en hematología /
por: Vives i Corrons, Joan Lluís

S116: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON—TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
por: Kuo, K, et al.
Publicado: (2022)

Mitochondrial Pyruvate Carrier Subunits Are Essential for Pyruvate-Driven Respiration, Infectivity, and Intracellular Replication of Trypanosoma cruzi
por: Negreiros, Raquel S., et al.
Publicado: (2021)

Association of Matrix Metalloproteinase 9 C-1562T Polymorphism with Genetic Susceptibility to Myocardial Infarction: A Meta-Analysis
por: Juan, Zhang, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_go28u4bhlq51gtgmtu759l0gt5